We previously reported that macrophages treated with a TLR9 agonist in combination with an anti-PD1 antibody acquired a phenotype characterized by immunosuppressive and pro-tumor activity, as demonstrated in vivo and in vitro [56]. This evidence concerns the gene TLR9 and neoplasm.